RE:2024hopeforthebest, "Well that does not explain the free fall in the Czo stock price in 2023..."
You are always obsessing about what other people think. You have to learn to think for yourself. Stop obsessing about the price(ie., what others think) and start obsessing about what is being built. It would be sad if you couldn't see what is being built until someone on BNN makes CZO a Top Pick and you finally get excited with the volume not wanting to be left out.
There is arguably $100 million worth of real value in AEZS and as a merger of equals CZO can be seen similarly valued. It can be seen as a $200 million deal. Ronnie Miller, arguably the most important biotech executive in Canada in the last 20 years, is "thrilled" with how AEZS's assets can complement CZO's growth plan.
Key events are all lined up...
With this merger CZO's path is stronger than ever!
1) A North American growth hormone deficiency diagnostic deal. Novo Nordisk paid ~C$250 million(cash, equity) plus tiered royalties. H.C. Wainwright had a US$15 target price for AEZS likely substantially due to its diagnostic test which could be approved for its key market(children) in 2024 and relicensed for North America.
2) A PGX deal in the $4 billion CoQ10 market according to Gilles. PGX smashed the industry gold standard in the University of Albert trial. At the AGM Gilles said CZO is in talks with serious companies who understand the unique selling point of bioavailability. What could gold standard market share be in a $4 billion market.
3) 100L PGX scale-up and the decision to go commercial in the $1 billion immune booster market. PGX-YBG has been 5X more immune stimulative in human cell-lines and could set a new gold standard for purity. What could gold standard market share be in this $1 billion market in the much larger immune booster market.
4) Avenanthramide safety/tolerability, preliminary efficacy clinical results. CZO says this could be CZO's biggest product. The NSAID market is $50 billion per year.
5) Avenanthramide pill partner expected with successful Phase I/IIa safety/tolerability and potential preliminary efficacy data in patients suffering mild inflammation.
6) Fibrosis clinical trial decision and regulatory filing. Dr. Martin Kolb says PGX-YBG could profoundly change the treatment landscape. Avalyn raised C$80 million going into its Phase I clinical trial.
7) Wound healing data and partner. Dr. Li talked about Intel Inside given the breadth of application. CZO has already past the gold standard model others use. Gilles calls it a "home run". Wound healing claims for cosmeceuticals can also be advanced.
8) AIM Biologicals Phase I clinical trial decision in billion dollar potential market.
9) Launch of beta glucan and avenanthramide powders with Symrise.
10) CZO's major client initiates reordering.
11) Malted avenanthramide for the neutraceutical market. They can now produce from one plant what four could produce with the same input. Claims could be strengthened with the success of the avenanthramide clinical trial.
12) Tax loss carryforwards of C$113.4 million as the decision to go commercial with PGX are made; including with potential serious partners.
13) Potential biotech bull market as interest rates are cut.